In this picture, featured in the Boston Globe, Alan sports a sign about the benefits of scientific research.
Fairbanks was selected to present at UMass’ Technology Transfer Center’s Early-Stage Life Sciences Technology Conference on April 5, 2017. The presentation will focus on our technology, IP, potential markets, sustainable competitive advantage, developmental stage, and future plans. Stay tuned for a release of our latest slide deck.
Alan Schneyer and Elissa Brown gave Fairbanks’ introductory pitch today to MassBio’s 2017 Cycle 1 MassConnect mentors. Fairbanks was one of four biotech startups selected by MassBio to join the only entrepreneur mentorship program in Massachusetts that dives deep into the life sciences. MassCONNECT matches entrepreneurs and founders with seasoned life sciences professionals to catalyze and commercialize innovation.
The MassCONNECT process involves a two-month mentorship where industry experts guide entrepreneurs as they seek to develop business plans, launch companies, and raise capital.
MassCONNECT mentors evaluate and provide feedback on commercial feasibility; identify strengths, weaknesses, opportunities and threats; and team up to furnish industry-specific business advice for innovative ideas in therapeutics, diagnostics, medical devices and health IT. Entrepreneurs gain invaluable advice and coaching on defining value proposition, developing pitches and building professional networks.
Click here for more information on today’s kick-off.
(December 2016) Boehringer-Ingelheim Pharmaceuticals (BI) selected Fairbanks from 30 applicants to compete for their Boston Innovation Prize. BI runs this competition to help sustain innovative pipelines for new breakthrough therapies by providing a Golden Ticket for Lab Central space (valued at $75,000) in Cambridge, MA. The panel of judges includes senior and founding members of Lab Central and BI’s venture capital fund, as well as other seed stage investor groups.
We’re growing! Fairbanks Pharmaceuticals is now Fairbanks Pharmaceuticals, Inc., incorporated in the state of Delaware and registered in the Commonwealth of Massachusetts.
Fairbanks Pharmaceuticals has been selected as a semi-finalist in the Diabetes Innovation Challenge sponsored by the T1D Exchange, the Massachusetts Medical Device Development Center (M2D2) at UMass, the Juvenile Diabetes Research Foundation (JDRF) and the American Diabetes Association (ADA).
The Challenge is a proposal- and presentation-based competition for small companies in the T1 and T2 space that are making real progress towards better outcomes for those diagnosed. It offers the chance to win in-kind awards and receive early and later-stage validation of their ideas and products specific to Type 1 and Type 2 diabetes.
Dr. Alan Schneyer, CEO/CSO and Co-founder of Fairbanks Pharmaceuticals, is the Principal Investigator (PI) of an SBIR grant from The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at The National Institutes of Health (NIH). The award begins immediately and funds our research that will identify a number of candidate compounds using our proprietary screening bioassay, comparing them for biochemical and biological properties, and testing the top candidates for biological activity in islet culture assays.
The award lasts for a one year period. It is anticipated that the successful completion of this Phase 1 award will lead to a larger Phase 2 award, which will allow testing the biological activity of lead compounds in animals. The goal of Fairbanks Pharmaceuticals, and this SBIR grant, is to develop compounds that lead to regeneration of insulin-producing beta cells to replace those lost to either type 1 or type 2 diabetes and thereby partially or completely eliminate diabetes in these patients. Stay tuned for progress reports….
On November 25th, 2014, Fairbanks Pharmaceuticals opened its research laboratory in Springfield, Massachusetts.
The space is located at 3601 Main St within recently renovated open lab space that has a wealth of shared facilities available to Fairbanks scientists.
In our first two weeks we have been screening libraries to identify candidate compounds that we can then test for effectiveness in treating diabetes in animal models. Its been a hectic start but now we are ready to focus on our research and hopefully make excellent progress.